Phathom Pharmaceuticals Inc
PHAT8.920USD
+4.229+90.19%
Close 06/06, 16:00（ET）Quotes delayed by 15 min
621.17MMarket Cap
LossP/E TTM
More Details of Phathom Pharmaceuticals Inc Company
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Company Info
Company codePHAT
Company namePhathom Pharmaceuticals Inc
IPO dateOct 25, 2019
Founded at2018
CEOMr. Steven Basta
Number of employees427
Security typeOrdinary Share
Fiscal year-endOct 25
Address100 Campus Drive
CityFLORHAM PARK
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code07932
Phone18777428466
Websitehttps://www.phathompharma.com/
Company codePHAT
IPO dateOct 25, 2019
Founded at2018
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Azmi Nabulsi
Dr. Azmi Nabulsi
Co-Founder, Chief Operating Officer
Co-Founder, Chief Operating Officer
929.34K
-2.52%
Dr. Asit Parikh, M.D., Ph.D.
Dr. Asit Parikh, M.D., Ph.D.
Independent Director
Independent Director
113.50K
+10.19%
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Independent Director
Independent Director
67.50K
+18.42%
Ms. Molly Henderson, CPA
Ms. Molly Henderson, CPA
Chief Financial and Business Officer
Chief Financial and Business Officer
62.79K
-43.33%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
46.51K
+29.16%
Mr. Michael F. (Mike) Cola
Mr. Michael F. (Mike) Cola
Independent Chairman of the Board
Independent Chairman of the Board
39.80K
+35.84%
Mr. Mark Stenhouse
Mr. Mark Stenhouse
Independent Director
Independent Director
30.00K
+53.85%
Mr. Theodore R. (Ted) Schroeder
Mr. Theodore R. (Ted) Schroeder
Independent Director
Independent Director
21.00K
--
Ms. Heidi K. Kunz
Ms. Heidi K. Kunz
Independent Director
Independent Director
--
--
Mr. Steven Basta
Mr. Steven Basta
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Azmi Nabulsi
Dr. Azmi Nabulsi
Co-Founder, Chief Operating Officer
Co-Founder, Chief Operating Officer
929.34K
-2.52%
Dr. Asit Parikh, M.D., Ph.D.
Dr. Asit Parikh, M.D., Ph.D.
Independent Director
Independent Director
113.50K
+10.19%
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Independent Director
Independent Director
67.50K
+18.42%
Ms. Molly Henderson, CPA
Ms. Molly Henderson, CPA
Chief Financial and Business Officer
Chief Financial and Business Officer
62.79K
-43.33%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
46.51K
+29.16%
Mr. Michael F. (Mike) Cola
Mr. Michael F. (Mike) Cola
Independent Chairman of the Board
Independent Chairman of the Board
39.80K
+35.84%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Fri, Jun 6
Update time: Fri, Jun 6
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Frazier Life Sciences Management, L.P.
17.15%
Medicxi Ventures (UK) LLP
10.69%
Abingworth Management Limited
5.01%
Invesco Advisers, Inc.
4.80%
BlackRock Institutional Trust Company, N.A.
4.17%
Other
58.18%
Shareholder Statistics
Shareholder
Proportion
Frazier Life Sciences Management, L.P.
17.15%
Medicxi Ventures (UK) LLP
10.69%
Abingworth Management Limited
5.01%
Invesco Advisers, Inc.
4.80%
BlackRock Institutional Trust Company, N.A.
4.17%
Other
58.18%
Type
Shareholder
Proportion
Venture Capital
20.26%
Investment Advisor
18.82%
Private Equity
17.76%
Investment Advisor/Hedge Fund
17.55%
Hedge Fund
8.13%
Individual Investor
4.28%
Research Firm
2.58%
Bank and Trust
0.39%
Pension Fund
0.27%
Other
9.96%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
309
70.28M
101.09%
-12.22M
2024Q4
311
70.95M
103.79%
-11.79M
2024Q3
293
76.11M
113.29%
+9.50M
2024Q2
284
61.82M
105.14%
-1.53M
2024Q1
280
58.85M
100.56%
-3.74M
2023Q4
274
57.52M
100.58%
-4.32M
2023Q3
267
60.33M
119.18%
-6.87M
2023Q2
263
58.95M
120.15%
+1.98M
2023Q1
253
46.63M
112.72%
-8.47M
2022Q4
251
44.09M
112.53%
-3.76M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Frazier Life Sciences Management, L.P.
10.11M
14.52%
--
--
Dec 31, 2024
Medicxi Ventures (UK) LLP
7.46M
10.72%
--
--
Dec 31, 2024
Abingworth Management Limited
3.50M
5.02%
--
--
Dec 31, 2024
Invesco Advisers, Inc.
3.37M
4.84%
-146.50K
-4.17%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.08M
4.42%
+355.55K
+13.06%
Dec 31, 2024
The Vanguard Group, Inc.
2.77M
3.98%
+83.24K
+3.10%
Dec 31, 2024
Ensign Peak Advisors, Inc.
2.53M
3.63%
-54.33K
-2.10%
Dec 31, 2024
New Enterprise Associates (NEA)
1.96M
2.81%
--
--
Dec 31, 2024
Wasatch Global Investors Inc
1.56M
2.24%
+1.31M
+531.29%
Dec 31, 2024
683 Capital Management LLC
1.02M
1.47%
+15.00K
+1.49%
Dec 31, 2024
View more
Related ETFs
Update time: Fri, Jun 6
Update time: Fri, Jun 6
Name
Proportion
Simplify Propel Opportunities ETF
4.82%
Virtus LifeSci Biotech Products ETF
0.93%
iShares Micro-Cap ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Biotechnology ETF
0.02%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
View more
Simplify Propel Opportunities ETF
Proportion4.82%
Virtus LifeSci Biotech Products ETF
Proportion0.93%
iShares Micro-Cap ETF
Proportion0.04%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
iShares Biotechnology ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
